biosimilars
Trump Prescription Drug Order Puts Spotlight on Price Tensions for Biosimilars
President Trump issued an executive order aimed at lowering prescription drug prices.
APRIL 25, 2025
FDA Approves First Interchangeable Biosimilars to Xgeva and Prolia
The FDA approved the first interchangeable biosimilar to Prolia (denosumab) and Xgeva (denosumab). Sandoz’s ...
MARCH 6, 2024
340B Participation May Hamper Biosimilars Uptake
Are hospitals participating in the federal 340B Drug Pricing Program less motivated to prescribe biosimilars over ...
AUGUST 16, 2023
Systematic Use of Lower-Cost Drugs Shown Not to Harm Cancer Outcomes
Use of generics and biosimilars instead of originator drugs reduces the cost of cancer treatment without ...
JANUARY 5, 2023
Oncology Stewardship Mitigates Financial Toxicity for Patients
Strategies such as dose rounding, biosimilar adoption and site-of-care optimization can help combat the immense ...
DECEMBER 21, 2022
Practical Considerations For Implementing Biosimilars In Oncology Practice
Nearly 8 years have passed since the 2015 FDA approval of filgrastim-sndz (Zarxio, Sandoz) under the Biologics ...
SEPTEMBER 19, 2022
FDA Approves Stimufend, Biosimilar for Neulasta
The FDA approved Stimufend, a biosimar for Neulasta, for patients with non-myeloid malignancies receiving ...
SEPTEMBER 12, 2022
Third Biosimilar to Bevacizumab Approved
The FDA approved bevacizumab-maly (Alymsys, Amneal Pharmaceuticals), a biosimilar to bevacizumab (Avastin, ...
APRIL 19, 2022
The Case for Switching to Rituximab Biosimilar
Switching from originator rituximab to rituximab-abbs can save an institution up to $13,000 annually per patient ...
FEBRUARY 16, 2022
UDENYCA® (pegfilgrastim-cbqv)
The rising cost of biological products for oncology supportive care creates an ongoing need for increased ...
NOVEMBER 20, 2020
Feds to Push for More Biosimilar Competition
The FDA and the Federal Trade Commission (FTC) announced they will take further action to stem anticompetitive ...
FEBRUARY 18, 2020
Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial Discounts
Pfizer announced that it is introducing three new biosimilars, ZIRABEV (bevacizumab-bvzr), RUXIENCE ...
FEBRUARY 14, 2020
